Review




Structured Review

MultiTarget Pharmaceuticals braf multitarget tki (vegfr, raf, pdgfr)
Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
Braf Multitarget Tki (Vegfr, Raf, Pdgfr), supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegfr-tki+multitarget/braf+multitarget+tki++vegfr++raf++pdgfr+/pmc09674888-28-4-5
Average 90 stars, based on 1 article reviews
braf multitarget tki (vegfr, raf, pdgfr) - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?"

Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

Journal: ESMO Open

doi: 10.1016/j.esmoop.2022.100638

Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " title="Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or ... " property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21

Techniques Used: Homologous Recombination, Control

Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC
Figure Legend Snippet: Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

Techniques Used: Clinical Proteomics, Mutagenesis, Expressing

Related Articles

other:

Article Title: Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
Article Snippet: , VEGFR-TKI (multitarget) , Sunitinib, pazopanib, sorafenib, cabozantinib, axitinib, lenvatinib.



Similar Products

90
MultiTarget Pharmaceuticals braf multitarget tki (vegfr, raf, pdgfr)
Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
Braf Multitarget Tki (Vegfr, Raf, Pdgfr), supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegfr-tki+multitarget/braf+multitarget+tki++vegfr++raf++pdgfr+/pmc09674888-28-4-5
Average 90 stars, based on 1 article reviews
braf multitarget tki (vegfr, raf, pdgfr) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MultiTarget Pharmaceuticals multitarget vegfr-tkis
Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
Multitarget Vegfr Tkis, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegfr-tki+multitarget/multitarget+vegfr+tkis/pmc08315452-181-12-14
Average 90 stars, based on 1 article reviews
multitarget vegfr-tkis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MultiTarget Pharmaceuticals vegfr-tki multitarget
Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
Vegfr Tki Multitarget, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegfr-tki+multitarget/vegfr+tki+multitarget/pmc06708252-3-1-2
Average 90 stars, based on 1 article reviews
vegfr-tki multitarget - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="100%" height="100%">

Journal: ESMO Open

Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

doi: 10.1016/j.esmoop.2022.100638

Figure Lengend Snippet: Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21

Article Snippet: , Vemurafenib Sorafenib , BRAF Multitarget TKI (VEGFR, RAF, PDGFR...) , No , M, L ≥3, KRAS G12D mutation , II , Recruiting NCT05068752.

Techniques: Homologous Recombination, Control

Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

Journal: ESMO Open

Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

doi: 10.1016/j.esmoop.2022.100638

Figure Lengend Snippet: Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

Article Snippet: , Vemurafenib Sorafenib , BRAF Multitarget TKI (VEGFR, RAF, PDGFR...) , No , M, L ≥3, KRAS G12D mutation , II , Recruiting NCT05068752.

Techniques: Clinical Proteomics, Mutagenesis, Expressing